Last updated: 31 January 2026.

Autism is a neurodevelopmental condition that affects how individuals communicate, perceive the world, and interact socially. It exists on a spectrum, which describes the varying ways it manifests in different people. Many autistic individuals have unique strengths, such as intense focus or exceptional creativity, however they often face challenges related to sensory overload, social isolation, and adapting to unpredictable situations.

On 27 August 2025, President Donald Trump announced that, according to the latest data, one in 31 children in the United States is now diagnosed with autism (Shaw et al., 2025; Vote In Or Out, 2025). Alarmingly, the prevalence among boys is significantly higher, with one in 12 affected, reflecting a male-to-female ratio of approximately four to one (Gallagher & Goodman, 2010), although some studies suggest a slightly higher ratio closer to five to one (Baio, 2014).

This marks an increase from previous estimates by the Autism and Developmental Disabilities Monitoring (ADDM) Network of the Centers for Disease Control and Prevention (CDC), which reported an autism rate of one in 36 (Zablotsky et al., 2017). Compared to the first recorded prevalence of less than one in 10,000 (Treffert, 1970), this represents a staggering 32,160 per cent increase over the last 50 years. Autism spectrum disorder (ASD) currently affects over 3.5 million Americans (Buescher et al., 2014).

Australian statistics reflect a similar upward trend. MacDermott et al. (2006) estimated that 0.6 per cent of Australian children—approximately one in 160—had been diagnosed with ASD. Barbaro and Dissanayake (2010) reported rates ranging from 0.4 per cent to 0.8 per cent among two-year-olds in Victoria, while Randall et al. (2016) found a sharp increase to 2.5 per cent (one in 40) among children aged four to five. Although methodological differences may account for some variation, it is also likely that these findings, which span a decade, reflect a genuine increase in ASD rates over time.

Globally, an estimated 70 million people are affected by ASD, with projections suggesting prevalence could reach 2 per cent of the world’s population by the end of 2025. However, the data we have presented here indicates this threshold has already been exceeded in several populations, particularly among boys. In response, governments have expanded access to medical, psychological, and educational support services—and while these efforts are necessary and commendable, they fail to identify and address the underlying causes. To date, no government has enacted substantive legislation to regulate or ban toxic chemicals increasingly implicated in autism risk by emerging research.

Possible Causes of Autism:

1. Genetics

The most common explanation offered to explain the cause of ASD is genetics. Early studies of twins indicated a genetic component to ASD, with higher concordance rates observed in identical twins compared to fraternal twins (Folstein & Rutter, 1977). However, the reliability of these early findings is limited by small sample sizes and methodological flaws. Moreover, twin studies face inherent challenges in isolating genetic influences from shared environmental factors.

While genetic factors have long dominated autism research, they fall short of explaining its rising prevalence. As Francis S. Collins, then Director of the National Institutes of Health, testified before the House Subcommittee on Labor-HHS-Education Appropriations, genes alone cannot account for the recent increase in chronic conditions such as diabetes, childhood asthma, obesity, and ASD, since changes in the human gene pool take much longer to occur (Collins, 2006, para. 15). Despite this, the majority of federal autism research funding continues to be directed toward genetic studies (Wright, 2012; Interagency Autism Coordinating Committee [IACC], 2012, p. 16; IACC, 2017, p. 59).

The most comprehensive twin study to date was conducted by Hallmayer et al. (2011), as part of a large-scale initiative by the State of California. A team of 16 leading geneticists was granted full access to birth records and tasked with quantifying genetic influence on ASD. Their findings revealed that genetics accounted for, at most, 38 per cent of autism cases—a figure the authors themselves caution may be an overestimate. It therefore follows that at least 62 per cent of ASD cases are attributable to non-genetic factors.

This conclusion is further supported by a recent study from the University of California, Davis’s Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, which estimated that 88 per cent of autism cases in the United States are characterised by regression. This suggests that acute toxic exposure is responsible for the majority of cases, not genetics (Ozonoff et al., 2018). Additionally, as most autism diagnoses occur in families with no prior history of ASD, this calls into question the sufficiency of a purely genetic explanation, suggesting that at best a genetic predisposition may exist which makes individuals more susceptible to the effects of environmental triggers (Love, 2024).

2. Definitions & Improved Diagnostics

The spike in autism numbers has led many to speculate whether these reflect a genuine increase in case numbers or are due to improvements in diagnosing cases that had previously gone undetected. Some have questioned whether revisions to the Diagnostic and Statistical Manual of Mental Disorders (DSM), from DSM-III to DSM-IV to DSM-5, could have resulted in inflated estimates. Others suggest that higher rates in American states such as California and New Jersey may be the result of families relocating to access better autism support services. However, evidence shows these factors fail to explain the increase.

In 1999, the California Department of Developmental Services reported a 273 per cent rise in autism cases between 1987 and 1998 (Byrd et al., 2002, p. 2). In response, the state legislature commissioned the MIND Institute to determine whether this increase was caused by improvements in diagnostic procedures or interstate migration. The team, led by paediatric epidemiologist Robert Byrd, found no support for either explanation. Most children served by Regional Centers were native-born, and there had been no significant influx into California that could account for the surge in autism numbers (Byrd et al., 2002, p. 5).

Hertz-Picciotto and Delwiche (2009) conducted a study to assess how much three specific factors contributed to the dramatic 600 to 700 per cent rise in autism cases in California between 1990 and 2006. The factors examined were: changes in diagnostic criteria, the inclusion of milder cases, and earlier age at diagnosis. They found that diagnostic changes accounted for a 120 per cent increase, milder cases for 56 per cent, and earlier diagnosis for 12 per cent, totalling 188 per cent. However, when compared to the overall rise, these factors explained only between 26.9 per cent (188/700) and 31.3 per cent (188/600) of the increase. In a later interview with Scientific American, Hertz-Picciotto emphasised that these factors “do not get us close” to explaining the full trend and called for a closer study of environmental factors (Cone, 2009, para. 13).

Another commonly suggested explanation for the increase lies in how autism has been defined over time. Autism was first included in DSM-III (1980). DSM-IV (1994) added Asperger’s Syndrome, while DSM-5 (2013) merged autism, Asperger’s, and pervasive developmental disorders into “autism spectrum disorders” (Autism Society, n.d., para. 5). Croen et al. (2002) proposed that changes in diagnostic criteria were responsible for the rising prevalence in California between 1987 and 1994, but Blaxill et al. (2003) identified issues in that analysis. Croen and Grether (2003) later agreed that “diagnostic substitution does not appear to account for the increased trend in autism prevalence”.

Barton et al. (2013) and Mazefsky et al. (2013) conducted separate studies which concluded that the more precise definition of autism spectrum disorder in the DSM-5 would likely result in fewer diagnoses. This prediction was supported by Maenner et al. (2014), who retrospectively analysed data from 6,577 children diagnosed under DSM-IV-TR criteria and found that applying DSM-5 diagnostic criteria would have resulted in an estimated 11.5 per cent decrease in the number of children diagnosed.

Additional concerns have been raised regarding how the definition of autism outlined in the Individuals with Disabilities Education Act (IDEA) may have affected prevalence estimates. Having not been updated since 2004, IDEA’s definition remains closely aligned with the DSM-5 (Harker & Stone, 2014). In addition, the American Psychiatric Association, which publishes the DSM, coordinated with the World Health Organization to ensure that the DSM-5 definition corresponded with the 11th edition of the International Classification of Diseases (ICD-11) (Regier et al., 2013).

Taken together, the evidence shows that changes in definitions and diagnostic practices fail to account for the sharp rise in autism prevalence, suggesting that other contributing factors warrant closer examination (DeSoto, 2010). This conclusion is further supported by the absence of a parallel increase in diagnoses among older adults. If improved diagnostics over time were responsible for the bulk of new case numbers, we would expect to see a significant number of individuals in their 50s and 60s being newly identified with ASD—yet such cases are largely non-existent.

3. Environmental Factors

In 2010, the Mount Sinai Children’s Environmental Health Center, in collaboration with Autism Speaks, convened a workshop entitled Environmental Causes of Autism and Learning Disabilities. The workgroup identified ten chemicals and compounds that are prevalent in the environment and suspected of contributing to developmental neurotoxicity. These included lead, methylmercury, organophosphate pesticides, organochlorine pesticides, polychlorinated biphenyls, endocrine disruptors, automotive exhaust, polycyclic aromatic hydrocarbons, brominated flame retardants, and perfluorinated compounds (PFCs) (Landrigan et al., 2012, p. A259).

In 2016, forty-seven leading U.S. experts in epidemiology, medicine, and public health formed Project TENDR (Targeting Environmental Neuro-Developmental Risks) and released a consensus statement asserting that environmental toxicants contribute to neurodevelopmental disorders, including autism (Bennett et al., 2016). The statement identified six key examples of neurotoxic chemicals: organophosphate pesticides, PBDE flame retardants, combustion-related air pollutants, lead, mercury, and PCBs (Bennett et al., 2016, pp. 118–119). Arthur Lavin, a Project TENDR member, argued that reducing exposure to these chemicals by just 20 per cent could lower the incidence of autism, ADHD, and learning disabilities by 15 to 40 per cent (Lavin, 2015, para 15).

While the consensus statements represent progress in attempting to identify environmental contributors to neurodevelopmental disorders, their findings simply echoed the already well-established toxicants identified by the Mount Sinai Children’s Environmental Health Center six years earlier–and seemed to conveniently avoid acknowledging any emerging environmental risks. For example, the dangers of lead had been recognised for fifty years; those of mercury for more than a century; organophosphates were originally developed as chemical weapons during World War II before being repurposed for agricultural use; concerns about organochlorine pesticides like DDT were recognised even before Rachel Carson published Silent Spring in 1962, the book that famously exposed the health and environmental risks of pesticide use; and the manufacture of PCBs was banned in the United States in 1979. Furthermore, the prevalence of all these substances has remained consistent or in decline over time (Nevison, 2014).

Although the cumulative, low-dose, non-linear, or synergistic effects of these toxicants still pose possible risks, by failing to identify chemical toxins with usage patterns that have increased in parallel with the rise in autism prevalence, the consensus statements merely reaffirm that these substances play a role in autism numbers but fail to account for the sharp increase in diagnoses that began in the late 1980s.

It is also important to note that the consensus statement disclosed that Project TENDR received funding from the John Merck Fund. Given Merck & Co.’s role as a major vaccine manufacturer, and broader concerns around funding bias, this connection raises legitimate questions about potential conflicts of interest and whether it may have limited the findings presented by the Project.

4. Vaccination

Among the most compelling arguments linking vaccines to autism is the consistent pattern of parental observation. Across thousands of documented cases, parents report how their child was developing typically until receiving routine vaccinations, often administered during scheduled ‘well baby’ visits, after which the child experienced a regression. Common adverse symptoms include fever, rashes, loss of speech and motor coordination, lack of eye contact, flat affect, behaviours associated with autism spectrum disorder, and even death. These accounts are strikingly common, and consistent in both timing and presentation.

These observations represent evidence that is both significant and undeniable yet are often dismissed by medical professionals who deny any causal link and offer no alternative explanation or meaningful support. Many parents who were once fully accepting of vaccination without question become anti-vaxxers immediately after observing a sudden developmental regression in their child. Notably, there is no equivalent phenomenon in which individuals who believe vaccines to be harmful reverse their stance following a comparable personal epiphany. This dichotomy helps explain the growing number of parents, often simply labelled “hesitant”, who consciously reject further vaccinations for their children following such experiences.

The logic here is straightforward. When conflicting claims arise—one from parents who have witnessed harm in their children that is consistent with product insert warnings and scientific literature, and another from government agencies and pharmaceutical representatives with vested financial interests in the very products they claim are universally safe—the rational response is not blind trust, but to further examine the evidence. After more than 30 years of personally reviewing the evidence, it has become apparent that parental accounts correspond far better with documented adverse events and scientific findings, than the official narrative which fails to reconcile with observable data and is frequently supported by questionable industry-sponsored research.

About that Science…

Within the first hour of birth, newborns are injected with a range of chemical substances. The first injection, vitamin K, is not listed on the vaccine schedule because, for all intents and purposes, it is not classified as a vaccine. The schedule only includes injections intended to protect against infectious diseases such as measles, polio, and hepatitis. Vitamin K does not fit that category, it is a preventive intervention administered to reduce the risk of vitamin K deficiency bleeding (VKDB), and therefore not a vaccine by definition.

However, the product safety insert for the vitamin K injection includes a black box warning, noting that severe reactions, including fatalities, have been reported after it was administered (Murphy, 2006; Pfizer Inc., 2021). In addition to the active ingredient, phytonadione (vitamin K1), the injection contains benzyl alcohol—a known neonatal toxin associated with “gasping syndrome” in premature infants (Cuzzolin, 2018). It also contains polyoxyethylated fatty acid derivatives, synthetic emulsifiers that, while generally regarded as safe, have not been adequately studied in newborns. The injection has also been linked to anaphylaxis, cardiac and/or respiratory arrest, and shock—even on first exposure. Given the rarity of VKDB, some parents have questioned whether the risk–benefit ratio of this intramuscular injection makes it necessary (Loyal & Shapiro, 2020).

Following the vitamin K injection, the next dose administered to Australian newborns is the first of four scheduled hepatitis B vaccines, the necessity of which has also been contentious (Nation, 2025). The Australian Immunisation Program Schedule instructs parents to have their child vaccinated against hepatitis B at birth, and again at 2, 4, and 6 months of age (Australian Government Department of Health, 2025). Hepatitis B is primarily transmitted through intravenous drug use or sexual contact with infected individuals, exposures irrelevant to healthy babies. It is therefore unclear why newborns should be vaccinated against a disease they are unlikely to encounter until adulthood, especially when screening mothers and tailoring interventions would be more rational, although less profitable, than blanket administration (Dr. Drew Pinsky).

More concerning is the Hep B vaccine’s composition. According to the Engerix-B product insert, a single paediatric dose contains 250 micrograms (µg) of aluminium (GlaxoSmithKline Australia Pty Ltd, 2023).

Aluminium is the 13th element on the periodic table and, while it is the most abundant metallic element in Earth’s crust, it does not occur in its pure metallic form anywhere in nature (Encyclopaedia Britannica, 2025). Aluminium is also a known neurotoxin (Bishop et al., 1997; Finberg et al., 1986; Joshi, 1990; Lukiw et al., 2005; Petrik et al., 2007; Shaw et al., 2014; Tomljenovic & Shaw, 2011; Wisniewski et al., 1990) that can accumulate in an infant’s tissue, bone, and cross the blood-brain barrier where it may deposit in the brain (Fanni, 2014; Gherardi, 2015; Halkman, 2024; Mold, 2018; Tomljenovic & Shaw, 2011).

The Engerix-B vaccine uses aluminium as an adjuvant to trigger an inflammatory response, activating the immune system and helping the body recognise and build immunity against the hepatitis antigen in the formulation. Because aluminium does not occur in nature, the human body has not evolved to recognise it, which is why, when injected, it provokes such a strong immune response (HogenEsch, 2018).

Most significantly, the quantity of aluminium injected with each hepatitis B dose far exceeds the established safety threshold of 4 to 5 µg/kg/day. Quantities above this limit, have been associated with a higher likelihood of neurodevelopmental delay in infants (Bishop, 1997; Movsas et al, 2013; Thomas, 2025a; U.S. Food and Drug Administration, 2004). This initial dose marks the beginning of a series of aluminium-containing injections, effectively saturating the infant’s system with repeated exposures over the first years of life (Aluminium per dose vaccine graph).

The Hep B product insert also lists a range of serious possible side effects including: Apnoea, or the temporary cessation of breathing; asthma; Bell’s palsy; eczema; encephalopathy; Guillain–Barré syndrome; herpes zoster, commonly known as shingles; meningitis; palpitations; seizures; Stevens–Johnson syndrome; tachycardia; and transverse myelitis—many of which have now become normalised in Australian infants.

Equally concerning is the fact that the safety study submitted to regulatory authorities for the original hepatitis B vaccine, licensed for use in neonates, involved only 143 children who were monitored for adverse reactions for a total of just five days. This falls far short of the long-term observation periods required for pharmaceutical products and fails to meet even the most basic standards of safety testing. This is documented in the FDA’s Summary Basis for Regulatory Action for the Engerix-B vaccine, which was approved in the United States and later adopted globally, including in Australia (ChaunceysGarden, 2025, 13:20; Miller, 2016b, p. 50).

Furthermore, no true placebo comparator was used in the Hepatitis B vaccine safety study. Instead of administering a saline injection, the control group received an alternative adjuvant-containing formulation (Antic, 2025; Miller, 2016b). Since adjuvants are intended to provoke an immune response, comparing two adjuvanted formulations presupposes that any adverse effects will likely appear in both the study and control groups. This allows researchers to claim the vaccine is safe even when adverse reactions occur, because although harm is observed in the study group, it is consistent with the harm experienced by the control group. Such study methodology conceals harm by making it appear unremarkable.

Moreover, this is not an isolated case. None of the early childhood vaccines have been adequately tested in double-blind, placebo-controlled trials, which remain the benchmark for assessing safety and efficacy of pharmaceutical products (Antic, 2025; ChaunceysGarden, 2025, 14:05). This absence of adequate testing undermines the credibility of all published safety claims for childhood vaccines (Attorney Aaron Siri debates Dr. Jake Scott re: inert placebo studies).

Most significantly, the potential risks associated with the hepatitis B vaccine, discussed in the previous section, may be further compounded if the infant’s mother received vaccinations during pregnancy. For example, some influenza vaccines, which are commonly recommended for pregnant women, still contain thimerosal, a mercury-based preservative. Thimerosal consists of 49.6 per cent ethylmercury, a substance also recognised as a neurotoxin (Grandjean & Landrigan, 2014; Spectrum Chemical Mfg. Corp., 2022). It’s important to note that the influenza vaccine has never been tested for safety or licensed for administration to pregnant women (Attorney Aaron Siri discusses Influenza vaccine safety studies for pregnant women).

Studies indicate that ethylmercury can cross the placental barrier and accumulate in the developing foetal brain (Redwood, 2025, p. 14; Agency for Toxic Substances and Disease Registry, 2011). This exposure alone is cause for concern, however research indicates that infants exposed to both mercury and aluminium toxicants, such as those injected from the hepatitis B vaccine, could experience a 200–900 per cent greater inflammatory response than from either metal alone (Alexandrov et al., 2018). This heightened inflammatory response in the brain can result in encephalopathy, which has been associated with autism, multiple sclerosis, and Alzheimer’s disease (Wong, 2022).

When Aluminium is ingested from food or environmental contamination, only 0.1 per cent is absorbed into the body. In contrast, aluminium injected through vaccination results in 100 per cent absorption (Thomas, 2025). Furthermore, injected aluminium is not excreted by urine in the same way as when ingested (Fewtrell, 2011; Thomas, 2025). Considering the limited capacity of the neonatal liver and kidneys to metabolise and excrete xenobiotics, these substances may not be fully cleared before the next scheduled round of vaccinations is administered (Alcorn & McNamara, 2002; Corkins et al., 2019; Hines, 2008; Kearns et al., 2003; Rhodin et al., 2009). Studies in mice injected with aluminium doses equivalent to those received by human infants under the standard vaccination schedule show that aluminium accumulates in the brain and is associated with neurological damage (Shaw, 2012).

It has also been shown that administering paracetamol to infants, such as Panadol or Tylenol, which both contain the active ingredient acetaminophen, can exacerbate the toxic effects of aluminium from vaccinations. Acetaminophen metabolites have been detected in urine and shown to cause depletion of glutathione (Ben-Shachar, 2012), which is essential for binding and transporting heavy metals like aluminium to the liver for excretion (Khan, 2012). This raises serious concerns about cumulative toxicity during early neurological development (Palevsky, 2023).

Update: Emerging research suggests that the neuroinflammatory and neurodegenerative effects of aluminium accumulation in the brain post-vaccination may be further aggravated by even moderate levels of electromagnetic radiation, such as those emitted by mobile phones and Wi-Fi routers—through mechanisms that increase blood-brain barrier permeability and oxidative stress (Ushakov, 2025).

Vaxxed versus unvaxxed

Large-scale, randomised studies comparing vaccinated and unvaccinated children remain conspicuously absent from the scientific literature—not because they’re infeasible, but because pharmaceutical interests have consistently declined to support or publish them. These decisions are typically justified by citing “ethical restrictions”, on the grounds that withholding vaccines from a control group poses an unacceptable risk, even when such trials could yield valuable data (Kass et al., 2013).

In the absence of such trials, American Amish communities offer a naturally occurring comparison group, as children in these populations often remain unvaccinated in accordance with the community’s religious and cultural practices. Reports have consistently noted unusually low rates of autism within Amish populations, with prevalence figures ranging from approximately one in 3,300 (3/10,000) to one in 1,500 (11/16,000) (Hookway, 2024).

Critics frequently respond to these findings by asserting “there is no scientific evidence” linking the low incidence of autism among the Amish to their abstention from vaccination (NeuroLaunch Editorial Team, 2024). Yet these rebuttals typically rely on denial, deflection, and unsupported claims—equally lacking in credible scientific evidence. The phrase “no scientific evidence” functions less as a genuine critique than as a rhetorical ploy used to discredit an otherwise unexplained phenomenon. In the absence of any industry-provided, large-scale comparative studies, the implications of the Amish example demand further examination (Olmsted, 2005).

Alternatively, some doctors have turned to compiling observational data from their own patient cohorts, using naturally occurring populations to explore long-term health outcomes (Lyons-Weiler & Thomas, 2020; Mawson et al., 2017). These studies aren’t driven by anti-vaccine ideology, as critics often claim (Science Feedback, 2020), they represent an attempt to investigate questions that the pharmaceutical industry has systematically avoided. Yet whenever doctors publish their findings, they’re not only criticised for their methodological limitations—they’re often discredited (IJERPH Editorial Office, 2021), vilified (Gorski, 2020), and even stripped of their medical licences (Thomas, 2025b). The taboo surrounding this subject has created an environment in which questioning the official narrative is treated as a threat to public safety rather than a contribution to scientific inquiry.

Ironically, the same lack of gold-standard study criteria used to dismiss these vaccine-critical studies is seldom applied to research asserting that childhood vaccines are unequivocally safe. As illustrated in the discussion of the hepatitis B vaccine, most vaccine safety studies rely on short-term data, use alternative comparators rather than true placebos, and rarely examine long-term health outcomes. Reflecting these limitations, the vaccine inserts for every childhood injection in the United States include a disclaimer at Section 13.1 stating that: “This product has not been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility”.

While the CDC mandates the inclusion of this warning, Australia’s Therapeutic Goods Administration (TGA) does not. Consequently, Australian product inserts typically end at Section 10 and use more generalised language to convey similar cautions. In many cases, where critical safety information should be provided, the inserts simply state “No data available”. This demonstrates just how limited the safety data is for vaccines across the entire childhood immunisation schedule. (Engerix-B: U.S. product insert versus Australian product insert)

It also reveals a clear double standard: doctors conducting important independent research are punished and discredited for publishing studies the industry refuses to undertake, while industry-backed studies must be accepted as true even when they fail to meet the most basic levels of safety testing. This is not science—it’s censorship designed to create the illusion of scientific “consensus”. But there can be no credible consensus if all opposing voices and opinions are silenced (Parliament of Australia, 2024).

As Marcia Angell, former editor-in-chief of the New England Journal of Medicine, wrote in her 2009 article, Drug Companies & Doctors: A Story of Corruption:

“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.” (Angell, 2009).

John P.A. Ioannidis, Professor of Medicine at Stanford University and former Editor-in-Chief of the European Journal of Clinical Investigation, echoed similar concerns. In his seminal 2005 paper published in PLOS Medicine, he stated:

“It can be proven that most claimed research findings are false.” (Ioannidis, 2005).

His analysis revealed that research outcomes are especially unreliable when driven by financial incentives, institutional bias, and academic pressure—conditions that foster conflicts of interest and compromise scientific integrity.

Richard Horton, Editor-in-Chief of The Lancet, voiced similarly damning concerns. In a 2015 editorial, he wrote:

“The case against science is straightforward: much of the scientific literature, perhaps half, may simply be untrue. Afflicted by studies with small sample sizes, tiny effects, invalid exploratory analyses, and flagrant conflicts of interest, together with an obsession for pursuing fashionable trends of dubious importance, science has taken a turn towards darkness.” (Horton, 2015).

These admissions from some of the most influential figures in scientific publishing reveal a research culture compromised by conflicts of interest, commercial influence, institutional self-interest, and deception.

So where am I going with this?

As I reflect on the excessive word count of what was meant to be a brief introduction to some foundational research I’d compiled, I find myself wondering how anybody could still dismiss the link between vaccines and autism, because to do so requires ignoring mountains of research explaining the link; a distinct lack of safety data disproving a link–not only for individual vaccines but for the cumulative effects of the full vaccine schedule (Miller, 2016a; Siri, 2025b; Stand for Health Freedom v. Centers for Disease Control and Prevention, 2025); the alarming list of toxic ingredients and warnings listed on every vaccine insert (GlaxoSmithKline Australia Pty Ltd, 2023); the absence of any adequate “official” explanation for the dramatic rise in ASDs over recent decades; and the fact that vaccine injury compensation has awarded damages for autism. According to a legal review of the Vaccine Injury Compensation Program, autism has been acknowledged as part of compensated vaccine-induced brain injury (Holland et al., 2011).

It also requires overlooking the fact that the childhood vaccine schedule in Australia has expanded in direct parallel with the global surge in autism diagnoses—from just three vaccines in the mid 1960s, to around a dozen by the 1980s, and now to approximately 54 required doses by age 16. This trajectory also coincides with a dramatic rise in pharmaceutical industry profits (Holland, 2025). Ignoring this link also means turning a blind eye to the extensive history of criminal convictions and regulatory violations committed by a corrupt, profit-driven pharmaceutical industry (Good Jobs First, 2025; “List of largest pharmaceutical settlements”, 2024; Pharmaceutical Technology, 2022; U.S. Department of Justice, 2025).

Most of all, denying the vaccine-autism link requires overlooking the tens of thousands of parental accounts describing how their child’s life was changed forever after receiving a vaccine—including the account observed by the parent writing this post.

I predict that within the next five to ten years, the damage caused by vaccines on generations of children will no longer be deniable. The opinions of those who currently insist vaccines are perfectly safe and effective will fade like the pleas of those who once denied any link between smoking and lung cancer—another public health crisis that was fuelled by greed and deep pockets, the mendacity of which Big Tobacco managed to sustain for over 30 years.

Ironically, Big Pharma has employed many of the same tactics used by Big Tobacco throughout the 1960s, ’70s, and ’80s, including data suppression, falsification of scientific studies, bribery of doctors and health officials, and the financial incentivisation of hospitals and universities—all to proffer a false narrative and protect the income stream of an industry profiting at the expense of the health and lives of its clients (Abramson, 2022; Jensen, 2025; van den Berg, 2024). The parallels are unmistakable.

For more on pharmaceutical industry corruption, watch for my upcoming post:
COVID-19: Pandemic or Pasquinade.

But I’m also conscious of how difficult it can be for people to accept a viewpoint that differs so greatly from what they have been taught to believe, even when it’s supported by substantive evidence and practical logic. As Self-Persuasion Theory suggests, individuals are more likely to change their beliefs and attitudes through personal exploration and discovery than in response to someone else’s attempt to persuade them (Aronson, 2007).

So with that in mind, please feel free to click the PDF link below to download and share the annotated bibliography I’ve spent years compiling and carefully annotating for you to explore:

Download Annotated Bibliography: Studies Supporting a Causal Relationship Between Vaccination and Autism Spectrum Disorders v4.0 (3mb pdf).

Updated: 3 December 2025, with 17 new studies annotated.

adjuvant aluminium Autism element 13 encephalopathy Engerix-B thimerosal vaccine-autism link